Abbott announced that it will acquire St. Jude Medical in an effort to enhance its global scale and diversify its portfolio.
With the acquisition, Abbott will become a “premier medical device leader with top positioning in high-growth [CV] markets, including AF, structural heart and HF as well as a leading position in the high-growth neuromodulation market,” the company stated in a press release.
According to the release, St. Jude Medical’s strength in devices for cardiac rhythm management and treatment of HF and atrial fibrillation complements Abbott’s strength in devices for coronary intervention and transcatheter mitral valve repair, and will enable the combined company to compete in almost every facet of the CV market.
“The combined business will have a powerful pipeline ready to deliver next-generation medical technologies and offer improved efficiencies for health care systems around the world,” Miles D. White, chairman and CEO of Abbott, said in the release. The pipeline also includes products for diabetes, vision and neuromodulation, the company stated.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Cisco Closes $28 Billion Splunk Deal
Mar 19, 2024 by
CPI
Ropes & Gray Strengthens Antitrust Practice with New Partner
Mar 19, 2024 by
CPI
Biden Administration Supports Antitrust Suit Against FIFA
Mar 18, 2024 by
CPI
Apple in Talks to Incorporate Google’s Gemini AI Amid Antitrust Scrutiny
Mar 18, 2024 by
CPI
Appeals Court Revives Regeneron’s Antitrust Lawsuit Against Novartis Over Vision Treatment
Mar 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pricing Algorithms
Feb 28, 2024 by
CPI
Pricing Algorithms and Antitrust Enforcement: Sandboxes to the Rescue?
Feb 28, 2024 by
CPI
AI, Algorithmic Pricing, and Collusion
Feb 28, 2024 by
CPI
Competition & Collusion in a World of Algorithmic Pricing: Antitrust Risks & Enforcement Trends
Feb 28, 2024 by
CPI
Pricing Algorithms in Antitrust’s Sights?
Feb 28, 2024 by
CPI